Shares in Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) surged 13% in the first hour of trading after the company announced it had administered the first human dose of its experimental CAR-T cell therapy, HG-CT-1.
The treatment is designed for adults with relapsed or treatment-resistant acute myeloid leukaemia, a condition with few options and a poor prognosis.
Chief executive Vladislav Sandler described the milestone as a validation of years of research and an important step towards delivering a potentially life-saving therapy.
The trial will now assess the safety and effectiveness of the treatment, with further updates expected.
In early trading, the stock was up 43.4p at 360.9p.